India Pharma Scandal: Owner Arrested Over 21 Child Deaths
India Pharma Scandal
9th October 2025, Kathmandu
Indian authorities have initiated a major crackdown following a devastating public health crisis.
India Pharma Scandal
Police successfully arrested the owner of a pharmaceutical company, G. Ranganathan, in connection with the deaths of 21 children.
This is the latest development in the shocking India Pharma Scandal which has rocked the nation and alarmed global health bodies.
The company produced a Toxic Cough Syrup that contained a lethal industrial solvent. This tragic incident highlights systemic issues leading to a global Drug Regulatory Crisis.
Arrest and Criminal Charges
Indian police arrested 75-year-old G. Ranganathan at his Chennai residence. He owns the Tamil Nadu-based Srusan Pharma Unit, which manufactured the contaminated medicine.
Officials have filed serious charges against him. These include culpable homicide and adulteration of drugs.
This action signals a strong move toward accountability by the Indian government. Authorities were determined to find the man responsible for manufacturing the deadly concoction.
The Deadly Contamination Exposed
The tragedy unfolded after several young children in Madhya Pradesh died last month. The children had consumed a cough syrup, branded as Coldriff.
Post-mortem and subsequent lab tests confirmed the cause of death was poisoning. The Indian Ministry of Health later confirmed the presence of Diethylene Glycol (DEG) in the syrup.
DEG is an industrial chemical. Manufacturers sometimes use it as a cheap substitute for a pharmaceutical-grade solvent like propylene glycol.
However, DEG is highly toxic, causing irreversible kidney and liver damage. It proves fatal even in small quantities.
The confirmation of widespread Diethylene Glycol Contamination sent shockwaves through the country’s drug control system. Health experts immediately warned the public about the severe risks.
Global Health Repercussions
This incident is not an isolated one. The current scandal only adds to a growing international concern over the quality of certain Indian-made pharmaceuticals.
India is often referred to as the “pharmacy of the world,” but this reputation is now severely damaged. The industry faces intense scrutiny from global regulators.
The repeated discovery of a Toxic Cough Syrup in multiple international markets demonstrates a glaring failure in quality control mechanisms.
For example, as many as 68 children in Uzbekistan died after taking similar contaminated syrups imported from India between 2022 and 2023.
Prior to that, contaminated syrup from another Indian manufacturer was linked to the deaths of more than 70 children in the West African nation of Gambia in 2022.
These past events intensify the severity of the current crisis in India. These tragic precedents put millions of vulnerable consumers at extreme risk worldwide.
Addressing the Drug Regulatory Crisis
The recurring nature of the Diethylene Glycol Contamination cases exposes a deep-seated Drug Regulatory Crisis. The World Health Organization (WHO) has actively engaged with the matter.
WHO asked Indian authorities for urgent clarification. They specifically want to know if the latest batch of contaminated syrup was exported to other countries.
This inquiry reflects the international community’s profound loss of trust. Urgent structural reforms are now a global imperative. This crisis demands immediate and fundamental reforms in the drug manufacturing and monitoring process.
Regulators must ensure all raw materials, especially common solvents, are sourced from certified suppliers and undergo mandatory, rigorous testing for contaminants like DEG.
Companies cannot be allowed to cut corners on Good Manufacturing Practices (GMP); the production of a Toxic Cough Syrup indicates a severe lapse in basic hygiene and process control.
Furthermore, an integrated, nationwide digital system for batch tracking and quality assurance could provide real-time oversight. Implementing the technology is now a public health necessity.
Action and Accountability
Following the tragic deaths, both Madhya Pradesh and other states immediately banned the sale and distribution of Coldriff syrup.
Authorities quickly seized existing stocks to prevent further harm. The focus now shifts to delivering justice for the victims and preventing future catastrophes.
The arrest of the pharma company owner is a crucial first step toward accountability. However, the regulatory bodies and the government must act quickly and decisively.
They must restore confidence in the Indian pharmaceutical industry, which holds such a vital role globally.
Only a total overhaul of the system can overcome the current India Pharma Scandal and truly address the global Drug Regulatory Crisis. Lives depend on this comprehensive action.
For more: India Pharma Scandal
